Does COVID-19 increase the risk of neuropsychiatric sequelae? Evidence from a mendelian randomization approach

Figure 1 Mendelian randomization analysis testing (A) severe, (B) hospitalized and (C) all Covid-19 forms against the risk of neuropsychiatric/neurological disorders. Odds ratios with 95% confidence intervals and P value from Mendelian randomization analyses are reported for each disorder tested as outcome against the three forms of coronavirus disease 2019 tested as exposure, with the number of instrumental variants (#IVs) analyzed. MR: Mendelian randomization; AD: Alzheimer’s disease; GAD: Generalized anxiety disorder; OR: Odds ratios; CI: Confidence interval; NA: Not available. *Not available on MR-Base (see Data Availability statement or [5] for details).